AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)
Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%
AbbVie revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
AbbVie's revenue for the twelve months ending Jun 30, 2026 was $64.39B, up 10.4% year over year. For fiscal 2025 it was $61.16B, up 8.6% from the year before. Over ten years it grew 10.3% a year on average. The highest annual figure on record is $61.16B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.16B | +8.6% |
| FY2024 | Dec 31, 2024 | $56.33B | +3.7% |
| FY2023 | Dec 31, 2023 | $54.32B | -6.4% |
| FY2022 | Dec 31, 2022 | $58.05B | +3.3% |
| FY2021 | Dec 31, 2021 | $56.20B | +22.7% |
| FY2020 | Dec 31, 2020 | $45.80B | +37.7% |
| FY2019 | Dec 31, 2019 | $33.27B | +1.6% |
| FY2018 | Dec 31, 2018 | $32.75B | +16.1% |
| FY2017 | Dec 31, 2017 | $28.22B | +10.1% |
| FY2016 | Dec 31, 2016 | $25.64B | +12.2% |
| FY2015 | Dec 31, 2015 | $22.86B | +14.5% |
| FY2014 | Dec 31, 2014 | $19.96B | +6.2% |
| FY2013 | Dec 31, 2013 | $18.79B | +2.2% |
| FY2012 | Dec 31, 2012 | $18.38B | +5.4% |
| FY2011 | Dec 31, 2011 | $17.44B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.99B | +10.2% |
| Q1 FY2026 | Mar 31, 2026 | $15.00B | +12.4% |
| Q4 FY2025 | Dec 31, 2025 | $16.62B | +10.0% |
| Q3 FY2025 | Sep 30, 2025 | $15.78B | +9.1% |
| Q2 FY2025 | Jun 30, 2025 | $15.42B | +6.6% |
| Q1 FY2025 | Mar 31, 2025 | $13.34B | +8.4% |
| Q4 FY2024 | Dec 31, 2024 | $15.10B | +5.6% |
| Q3 FY2024 | Sep 30, 2024 | $14.46B | +3.8% |
| Q2 FY2024 | Jun 30, 2024 | $14.46B | +4.3% |
| Q1 FY2024 | Mar 31, 2024 | $12.31B | +0.7% |
| Q4 FY2023 | Dec 31, 2023 | $14.30B | -5.4% |
| Q3 FY2023 | Sep 30, 2023 | $13.93B | -6.0% |
| Q2 FY2023 | Jun 30, 2023 | $13.87B | -4.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.23B | -9.7% |
| Q4 FY2022 | Dec 31, 2022 | $15.12B | +1.6% |
| Q3 FY2022 | Sep 30, 2022 | $14.81B | +3.3% |
| Q2 FY2022 | Jun 30, 2022 | $14.58B | +4.5% |
| Q1 FY2022 | Mar 31, 2022 | $13.54B | +4.1% |
| Q4 FY2021 | Dec 31, 2021 | $14.89B | +7.4% |
| Q3 FY2021 | Sep 30, 2021 | $14.34B | +11.2% |
| Q2 FY2021 | Jun 30, 2021 | $13.96B | +33.9% |
| Q1 FY2021 | Mar 31, 2021 | $13.01B | +50.9% |
| Q4 FY2020 | Dec 31, 2020 | $13.86B | +59.2% |
| Q3 FY2020 | Sep 30, 2020 | $12.90B | +52.2% |
| Q2 FY2020 | Jun 30, 2020 | $10.43B | +26.3% |
| Q1 FY2020 | Mar 31, 2020 | $8.62B | +10.1% |
| Q4 FY2019 | Dec 31, 2019 | $8.70B | +4.8% |
| Q3 FY2019 | Sep 30, 2019 | $8.48B | +3.0% |
| Q2 FY2019 | Jun 30, 2019 | $8.26B | -0.3% |
| Q1 FY2019 | Mar 31, 2019 | $7.83B | -1.3% |
| Q4 FY2018 | Dec 31, 2018 | $8.31B | +7.3% |
| Q3 FY2018 | Sep 30, 2018 | $8.24B | +17.7% |
| Q2 FY2018 | Jun 30, 2018 | $8.28B | +19.2% |
| Q1 FY2018 | Mar 31, 2018 | $7.93B | +21.4% |
| Q4 FY2017 | Dec 31, 2017 | $7.74B | +13.9% |
| Q3 FY2017 | Sep 30, 2017 | $7.00B | +8.8% |
| Q2 FY2017 | Jun 30, 2017 | $6.94B | – |
| Q1 FY2017 | Mar 31, 2017 | $6.54B | – |
| Q4 FY2016 | Dec 31, 2016 | $6.80B | – |
| Q3 FY2016 | Sep 30, 2016 | $6.43B | – |
See a number that looks wrong?